Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)

Critical Care Medicine

Volumn 37, Issue 4, 2009, Pages 1185-1196

  Jaimes, Fabián ^a   De La Rosa, Gisela ^a   Morales, Carlos ^a   Fortich, Fernando ^a   Arango, Clara ^a   Aguirre, Daniel ^a   Muñoz, Álvaro ^b  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical trial; Coagulation; Heparin; Longitudinal studies; Organ dysfunction; Sepsis

Indexed keywords

HEPARIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SOFT TISSUE INFECTION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTICOAGULANTS; DOUBLE-BLIND METHOD; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; SEPSIS;

EID: 67650470156     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819c06bc     Document Type: Article

References (49)

1. Dhainaut JF, Shorr AF, Macias WL, et al: Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure. Crit Care Med 2005; 33:341-348
2. Kinasewitz GT, Yan SB, Basson B, et al: Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative microorganism [ISRCTN74215569]. Crit Care 2004; 8:R82-R90
3. Iba T, Kidokoro A, Fukunaga M, et al: Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock 2005; 23:25-29
4. Aird WC: Sepsis and coagulation. Crit Care Clin 2005; 21:417-431
5. Collins PW, Macchiavello LI, Lewis SJ, et al: Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 2006; 135: 220-227
6. Opal SM, Esmon CT: Bench-to-bedside review: Functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003; 7:23-38
7. Riewald M, Ruf W: Science review: Role of coagulation protease cascades in sepsis. Crit Care 2003; 7:123-129
8. Opal SM, Kessler CM, Roemisch J, et al: Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002; 30:S325-S331
9. Jaimes F, de la Rosa G: [Anticoagulation and sepsis: The opportunity for a new use of heparin?]. Biomedica 2006; 26:150-160
10. Griffin MP, Gore DC, Zwischenberger JB, et al: Does heparin improve survival in experimental porcine gram-negative septic shock? Circ Shock 1990; 31:343-349
11. Tanaka T, Tsujinaka T, Kambayashi J, et al: The effect of heparin on multiple organ failure and disseminated intravascular coagulation in a sepsis model. Thromb Res 1990; 60:321-330
12. Meyer J, Cox CS, Herndon DN, et al: Heparin in experimental hyperdynamic sepsis. Crit Care Med 1993; 21:84-89
13. Pernerstorfer T, Hollenstein U, Hansen J, et al: Heparin blunts endotoxin-induced coagulation activation. Circulation 1999; 100: 2485-2490
14. Boldt J, Papsdorf M, Piper SN, et al: Continuous heparinization and circulating adhesion molecules in the critically ill. Shock 1999; 11:13-18
15. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247
16. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
17. Warren BL, Eid A, Singer P, et al: Caring for the critically ill patient. High-dose anti-thrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286:1869-1878
18. Garner J, Jarvis W, Emori T, et al: CDC definitions for nosocomial infections. In: APIC Infection Control and Applied Epidemiology: Principles and Practice. Olmsted R (Ed). St. Louis, Mosby, 1996, pp A1-A20
19. Fleming TR, Harrington DP, O'Brien PC: Designs for group sequential tests. Control Clin Trials 1984; 5:348-361
20. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556
21. Marshall JC, Cook DJ, Christou NV, et al: Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-1652
22. Cook R, Cook D, Tilley J, et al: Multiple organ dysfunction: Baseline and serial component scores. Crit Care Med 2001; 29:2046-2050
23. Laterre PF, Garber G, Levy H, et al: Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study. Crit Care Med 2005; 33:952-961
24. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818 - 829
25. Lee E: Statistical Methods for Survival Analysis. Second Edition. New York, John Wiley & Sons, 1992
26. Putter H, Fiocco M, Geskus RB: Tutorial in biostatistics: Competing risks and multi-state models. Stat Med 2007; 26:2389-2430
27. Laird NM, Ware JH: Random-effects models for longitudinal data. Biometrics 1982; 38:963-974
28. Eichacker PQ, Natanson C: Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med 2007; 33:396-399
29. Minneci PC, Deans KJ, Cui X, et al: Antithrombotic therapies for sepsis: A need for more studies. Crit Care Med 2006; 34:538-541
30. Eichacker PQ, Natanson C, Danner RL: Surviving sepsis - Practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006; 355:1640-1642
31. Eichacker PQ, Danner RL, Suffredini AF, et al: Reassessing recombinant human activated protein C for sepsis: Time for a new randomized controlled trial. Crit Care Med 2005; 33:2426-2428
32. Cornet AD, Smit EG, Beishuizen A, et al: The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost 2007; 98:579-586
33. Robertson MS: Heparin: The cheap alternative for immunomodulation in sepsis? Crit Care Resusc 2006; 8:235-238
34. Ai YH, Zhang LN, Gong H, et al: [Clinical study of low molecular weight heparin therapy for sepsis]. Zhongguo WeiZhong Bing Ji Jiu Yi Xue 2005; 17:736-739
35. Zhang XJ, Ma XC: [Therapeutic effects of early administration of low-dose heparin in patients with severe sepsis]. Zhonghua Wai Ke Za Zhi 2006; 44:1209-1211
36. Levi M, Levy M, Williams MD, et al: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007; 176:483- 490
37. Costa V, Brophy JM: Drotrecogin alfa (activated) in severe sepsis: A systematic review and new cost-effectiveness analysis. BMC An-esthesiol 2007; 7:5
38. Bertolini G, Rossi C, Anghileri A, et al: Use of drotrecogin alfa (activated) in Italian intensive care units: The results of a nationwide survey. Intensive Care Med 2007; 33:426-434
39. Friedrich JO, Adhikari NK, Meade MO: Drotrecogin alfa (activated): Does current evidence support treatment for any patients with severe sepsis? Crit Care 2006; 10:145
40. Abraham E, Laterre PF, Garg R, et al: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
41. Jaimes F, Arango C, Ruiz G, et al: Predicting bacteremia at the bedside. Clin Infect Dis 2004; 38:357-362
42. Jaimes F, De La Rosa G, Gomez E, et al: Incidence and risk factors for ventilator-associated pneumonia in a developing country: Where is the difference? Respir Med 2007; 101:762-767
43. Jaimes F: A literature review of the epidemiology of sepsis in Latin America. Rev Panam Salud Publica 2005; 18:163-171
44. Vincent JL, Angus DC, Artigas A, et al: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31:834-840
45. Marshall JC, Vincent JL, Guyatt G, et al: Outcome measures for clinical research in sepsis: A report of the 2nd Cambridge Colloquium of the International Sepsis Forum. Crit Care Med 2005; 33:1708- 1716
46. ten Cate H: Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000; 28:S9-S11
47. Levi M, de Jonge E, van der Poll T, et al: Novel approaches to the management of disseminated intravascular coagulation. Crit Care Med 2000; 28:S20-S24
48. Lehmann C, Usichenko TI, Pavlovic D: Heparins in sepsis-induced disseminated intravascular coagulation: Low weight-high impact? Crit Care Med 2005; 33:1455- 1457
49. Hirsh J, Warkentin TE, Shaughnessy SG, et al: Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119:64S-94S